PSTX News and Press, Poseida Therapeutics Inc. From 04/13/23

Poseida Therapeutics Appoints Rafael G. Amado, M.D., to Board of Directors PR Newswire SAN DIEGO , April 13, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for pat...

Poseida Therapeutics Appoints Kristin Yarema, Ph.D., as President, Cell Therapy PR Newswire SAN DIEGO , April 11, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatmen...

2023-03-17 17:22:43 ET Gainers: SolarEdge Technologies ( SEDG ) +6% . SuRo Capital ( SSSS ) +5% . Cincinnati Financial Corporation ( CINF ) +5% . Northern Trust Corporation ( NTRS ) +4% . Arch Capital Group  ( ACGL ) +4% . ...

2023-03-09 17:56:27 ET Poseida Therapeutics press release ( NASDAQ: PSTX ): Q4 GAAP EPS of -$0.39 misses by $0.56 . Revenue of $10.05M (-67.8% Y/Y) misses by $21.7M . For further details see: Poseida Therapeutics GAAP EPS of -$0.39 misses by $0.56, revenu...

Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2022 PR Newswire Presented early data from Phase 1 trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 allogeneic CAR-T cell therapy programs at the European Society for Medical Oncology Immu...

Poseida Therapeutics Appoints Five New Members to Its Gene Therapy Scientific Advisory Board PR Newswire SAN DIEGO , March 1, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class...

Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations PR Newswire Vir...

Poseida Therapeutics to Present at H.C. Wainwright Cell Therapy Virtual Conference PR Newswire SAN DIEGO , Feb. 14, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments ...

Poseida Therapeutics to Host Third Annual Virtual R&D Day on February 22, 2023 Poseida Therapeutics to Host Third Annual Virtual R&D Day on February 22, 2023 PR Newswire SAN DIEGO , Feb. 8, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX...

Summary Poseida is emerging as a leader in the allogeneic cell therapy field. A deal struck with Swiss Pharma giant Roche last year involved a $110m upfront payment plus as much as $6bn in development and commercial milestone payments. The 2 companies will develop allogeneic cell th...